Nektar Therapeutics Financials - Benzinga

SPY766.55−0.62%QQQ737.78−0.90%BTC/USD83,659.17−0.93%DIA514.48−0.58%GLD379.10−3.64%TLT78.47−1.08%

Nektar Therapeutics

NKTRNASDAQ

Trade with Public

Trade with Public

$61.15

4.097.16%

Last update: Sep 28, 3:04 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Nektar Therapeutics Financials

Nektar Therapeutics (NKTR) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate

Benzinga Newsdesk

PRO
Nektar Therapeutics Q1 EPS $(1.82) Misses $(1.62) Estimate, Sales $10.860M Beat $10.636M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.82) per share which missed the analyst consensus estimate of $(1.62) by 12.35 percent. This is a 49.72 percent increase over losses of $(3.62) per share

Benzinga Newsdesk

PRO
Nektar Therapeutics Q4 EPS $(1.78) Beats $(2.59) Estimate, Sales $21.807M Beat $10.404M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.59) by 31.27 percent. This is a 442.31 percent decrease over earnings of $0.52 per share

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

PRO
Nektar Therapeutics Q3 EPS $(1.87) Beats $(2.69) Estimate, Sales $11.790M Beat $10.048M Estimate

Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(1.87) per share which beat the analyst consensus estimate of $(2.69) by 30.35 percent. This is a 29.7 percent increase over losses of $(2.66) per share

Benzinga Newsdesk

Earnings Scheduled For November 6, 2025

Benzinga Insights